Cronos Group (CRON) Expected to Announce Quarterly Earnings on Monday

Key Points

• Cronos Group will report Q1 2026 results before the open on Monday, May 11 at 8:30 AM ET; analysts expect EPS of $0.01 and revenue of $42.21 million.
• In the prior quarter (reported Feb. 26) Cronos beat estimates with EPS of $0.02 (vs. $0.01 consensus) and revenue of $58.39 million (vs. $38.51 consensus), showing recent outperformance.
• The stock trades around $2.66 with a market cap near $999 million; Wall Street’s consensus rating is a Hold with an average target of $2.30, and institutional buying has recently increased (notably Goldman Sachs).

Cronos Group (NASDAQ:CRON - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $42.21 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.01. The firm had revenue of $58.39 million during the quarter, compared to the consensus estimate of $38.51 million. Cronos Group had a negative return on equity of 1.12% and a negative net margin of 6.44%.

Cronos Group Stock Performance

Shares of NASDAQ:CRON traded up $0.02 during mid-day trading on Monday, hitting $2.66. 690,783 shares of the company traded hands, compared to its average volume of 1,397,698. The firm has a market cap of $999.00 million, a P/E ratio of -265.23 and a beta of 0.87. Cronos Group has a 52-week low of $1.81 and a 52-week high of $3.43. The firm's 50 day simple moving average is $2.59 and its 200 day simple moving average is $2.60.

Institutional Trading of Cronos Group

Hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in shares of Cronos Group by 291.6% in the first quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company's stock worth $118,000 after buying an additional 48,476 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Cronos Group by 84.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,076,405 shares of the company's stock worth $1,948,000 after purchasing an additional 493,161 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in shares of Cronos Group during the 2nd quarter worth $36,000. Legal & General Group Plc boosted its holdings in Cronos Group by 16.1% during the second quarter. Legal & General Group Plc now owns 195,368 shares of the company's stock valued at $374,000 after acquiring an additional 27,111 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Cronos Group by 192.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 89,683 shares of the company's stock valued at $171,000 after buying an additional 59,013 shares during the last quarter. 8.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Weiss Ratings lowered shares of Cronos Group from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday, March 2nd. TD Securities assumed coverage on shares of Cronos Group in a report on Tuesday, February 24th. They issued a "buy" rating for the company. Zacks Research lowered Cronos Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Cronos Group from a "sell" rating to a "hold" rating in a research report on Sunday, March 8th. Finally, Canaccord Genuity Group assumed coverage on Cronos Group in a research note on Tuesday, January 27th. They set a "buy" rating on the stock. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $2.30.

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group's business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company's branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.